Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 2
2007 2
2008 2
2009 1
2010 4
2011 6
2012 3
2013 2
2015 1
2016 1
2019 2
2021 6
2022 2
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
Metabolic and toxicological considerations regarding CGRP mAbs and CGRP antagonists to treat migraine in COVID-19 patients: a narrative review.
Takizawa T, Ihara K, Uno S, Ohtani S, Watanabe N, Imai N, Nakahara J, Hori S, Garcia-Azorin D, Martelletti P. Takizawa T, et al. Among authors: imai n. Expert Opin Drug Metab Toxicol. 2023 Dec;19(12):951-967. doi: 10.1080/17425255.2023.2280221. Epub 2024 Jan 12. Expert Opin Drug Metab Toxicol. 2023. PMID: 37925645 Review.
A multicenter, open-label, phase 3 study to evaluate the safety of fremanezumab for migraine, subcutaneously self-administered with an auto-injection device at institutional sites and at home.
Hirata K, Takeshima T, Imai N, Igarashi H, Shiosakai M, Inage M, Sakurai F, Ning X, Nakai M, Koga N. Hirata K, et al. Among authors: imai n. Expert Opin Drug Saf. 2023 Jan-Jun;22(6):447-454. doi: 10.1080/14740338.2023.2162038. Epub 2022 Dec 28. Expert Opin Drug Saf. 2023. PMID: 36578197
Early onset of efficacy with erenumab for migraine prevention in Japanese patients: Analysis of two randomized, double-blind, placebo-controlled studies.
Hirata K, Takeshima T, Sakai F, Imai N, Matsumori Y, Tatsuoka Y, Numachi Y, Yoshida R, Peng C, Mikol DD, Lima GPDS, Cheng S. Hirata K, et al. Among authors: imai n. Brain Behav. 2022 Mar;12(3):e2526. doi: 10.1002/brb3.2526. Epub 2022 Feb 24. Brain Behav. 2022. PMID: 35201674 Free PMC article. Clinical Trial.
40 results